Although the price hike attracted a news media firestorm, largely overlooked was the even more alarming decision by the drug’s previous manufacturer to eliminate distribution of the drug to outpatient pharmacies across America, a policy that continued after Turing acquired the drug. Developed more than 60 years ago, pyrimethamine, sold under the brand name Daraprim, has long been off-patent and was until now affordable and widely distributed. But it is now available only to patients outside of a hospital via a single distributor. That makes access — not just cost — a huge challenge for patients and medical professionals nationwide.
Read Full Article »
